Background: Although clinical trials with sunitinib and sorafenib in metastatic renal cell carcinoma (mRCC) have included patients with moderate renal insufficiency (RI), the incidence of renal toxicity induced by their administration as well as the safety of these agents in patients with more severe renal insufficiency has not been extensively reported.
introduction
The Von Hippel-Lindau is a tumor suppressor gene, the product of which regulates the production of vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and a number of other hypoxia-inducible proteins [1] [2] [3] [4] . These factors bind to their specific tyrosine kinase receptors on endothelial cells and promote tumor angiogenesis and subsequent tumor growth.
Sunitinib and sorafenib are small oral tyrosine kinase inhibitors of VEGF and PDGF and related receptors [5] [6] [7] [8] [9] [10] . Although clinical trials with sunitinib and sorafenib in metastatic renal cell carcinoma (mRCC) have included patients with moderate renal insufficiency (RI) [creatinine clearance (CrCl) 30-50 ml/min], the incidence of renal toxicity induced by these agents in patients with more severe renal insufficiency has not been extensively reported.
Four phase I clinical studies evaluated the safety of sorafenib in patients with refractory solid tumors in patients with normal renal function (n = 71), patients with mild renal impairment (CrCl 50-80 ml/min, n = 24) or moderate renal impairment (CrCl 30-50 ml/min, n = 4). Three of these studies excluded patients with creatinine (Cr) > 1.5 · upper limit of normal (ULN) [11] [12] [13] [14] and did not specify dose adjustments for renal toxicity. A phase III trial, which examined sorafenib in patients with cytokine-refractory advanced renal cell carcinoma (RCC), did not mention renal toxicity and eligibility criteria included only patients with 'adequate renal function' [10] .
Less data is available for sunitinib with regards to safety in patients with renal dysfunction. Three phase I clinical trials were conducted, but only one study included patients with RCC (n = 4 of 28, 14%) with serum Cr < 1.5 · ULN or CrCl > 40 ml/min and Cr trend following initiation of therapy was not elaborated upon [7, 15, 16] . Two phase II clinical trials included patients with adequate renal function without specified parameters [17, 18] and of these, one trial reported 9 of 63 patients (14%) with grade 2 Cr elevation [17] . The phase III sunitinib trial in patients with treatment-naive RCC included patients with adequate renal function [19] . In this study, 66 of 375 patients (18%) had increased Cr of all grades.
The purpose of this retrospective review was to further characterize the effect of sorafenib and sunitinib on renal function in mRCC patients with baseline renal insufficiency and also to characterize RCC patients who develop renal insufficiency during treatment with these agents.
patients and methods
All patients with mRCC who received at least 3 months of treatment with either sunitinib or sorafenib at the Cleveland Clinic Taussig Cancer Institute were retrospectively identified as part of an institutional review boardapproved chart review protocol. Patients with the presence of RI before therapy or development of renal insufficiency during treatment were selected from this group and included in the present analysis. Renal insufficiency was defined as serum Cr ‡ 1.9 mg/dl before therapy and/or CrCl £ 60 ml/min for ‡ 3 months before treatment. Development of renal insufficiency was defined as an increase in Cr > 20% compared with baseline. Development of proteinuria is not reported in this study due to lack of complete data. CrCl was estimated using the Cockcroft-Gault method.
statistical methods
Patient data were collected retrospectively via electronic medical record chart review. Outcomes including overall response (OR), tumor shrinkage (TS) and progression-free survival (PFS) were recorded per investigator assessment using RECIST criteria [20] .
Categorical data, such as gender, histology, prognostic risk factors, the number of patients requiring dose reductions, adverse events and OR, were summarized as frequency counts and percentages [21] . Quantitative data, such as age, Cr, CrCl, interval to maximum RI and TS, were summarized as medians and ranges. Median PFS was calculated using the method of Kaplan and Meier. The Wilcoxon rank sum test was used to compare patients with RI at on-study to those who developed it with respect to maximum Cr and interval to maximum RI. All analyses were conducted using SAS 8.1 (SAS Institute Inc., Cary, NC).
results
A total of 39 patients were identified: 21 patients who initiated sunitinib or sorafenib therapy with preexisting RI and 18 patients who developed RI during treatment. Table 1 summarizes the patient characteristics. All but two patients had prior nephrectomy and 62% of patients had received prior systemic therapy. No patients received prior radiation therapy. Ninety percent of patients had an Eastern Cooperative Oncology Group performance status of zero or one.
patients with renal insufficiency at start of treatment
Of patients with RI at start of treatment, 10 of 21 (48%) were receiving a diuretic (hydrochlorothiazide, loop diuretic), 8 of 21 (38%) were cardiovascular medications (angiotensin receptor inhibitor, angiotensin receptor blocker) and 3 of 21 (14%) were receiving a bisphosphonate. Of patients who developed RI while on therapy, 9 of 18 (50%) were receiving a diuretic, 10 of 18 (56%) cardiovascular medications and 2 of 18 (11%) a bisphosphonate. Four patients received reduced dose of therapy (400 mg daily of sorafenib) as the starting dose per treating physician discretion. In these patients, Cr decreased by any amount in 43% of patients and increased by any amount with RI reaching its maximum at a median of 4.6 months (range 0.9-24.5). For both groups, the maximum serum Cr reached during treatment was similar (2.3 and 2.4 mg/dl, P = 0.84).
However, patients with RI at the start of treatment had a longer interval to maximum RI compared with patients who developed RI during treatment (6.6 versus 4.6 months); the difference, however, was not statistically significant, P = 0.70.
Our study included two patients on dialysis. One patient was started on dialysis following bilateral nephrectomy before VEGF therapy. This patient was started on sunitinib 50 mg 4 weeks on/2 weeks off and completed two cycles with grade 1 nausea and diarrhea. Therapy was stopped after two cycles secondary to progression of disease. The second patient was started on dialysis due to chronic renal insufficiency in the remaining kidney. This patient was started on sorafenib and dose was reduced at the beginning of the treatment. The patient continued to receive sorafenib while on dialysis without complications, though the treatment was stopped following two cycles secondary to progression of disease. Cr, creatinine; CrCl, creatinine clearance; HD, hemodialysis; RI, renal insufficiency. Table 3 . Non-renal toxicity RI at start of treatment RI developed during treatment Sorafenib (n = 13)
All grades, n (%)
All grades, n (%) original article
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Of patients with RI at the start of treatment, dose reduction was needed in 52% of patients secondary to toxicity and two patients (10%) discontinued therapy due to toxicity. Of the patients who developed RI on treatment, dose reduction was carried out in 50% of patients and three patients (17%) discontinued therapy due to toxicity. Overall, dose reduction was required in 51% of patients, of which 23% was secondary to elevated serum Cr and 28% was due to other toxicity.
The most commonly reported toxic effects (all grades) in both groups receiving either therapy were fatigue (85%), handfoot syndrome (HFS, 51%) and diarrhea (51%) ( Table 3) .
Five patients (24%) who had preexisting RI achieved PR, 13 patients (62%) had SD as their best response and PD occurred in 3 patients (14%) ( Table 4 ). Estimated PFS was 10.2 months. Of the patients who developed RI on treatment, 1 patient (6%) achieved complete response, 5 (28%) achieved PR, 10 (56%) had SD and 2 (11%) had PD as the best response. Median PFS was 11.7 months.
Overall, 21% of patients were hypertensive at baseline (systolic blood pressure > 150 mmHg and/or diastolic pressure > 90 mmHg). Between the two groups, there was no correlation between baseline blood pressure and either baseline CrCl or baseline serum Cr (P > 0.44 in all cases). There were no significant changes in blood pressure when compared with baseline in either group and no correlation between changes in blood pressure and changes in renal function.
discussion
This retrospective analysis suggests that sunitinib and sorafenib can be safely administered to mRCC patients with baseline renal insufficiency. In the present study, a significant percentage of patients required dose modifications. This is comparable to other studies. Efficacy and safety of sorafenib in patients with renal impairment was recently studied by Parsa et al., who defined renal insufficiency as calculated CrCl £ 60 ml/min. They concluded that sorafenib can be safely administered to patients with renal impairment; however, dose adjustment was required or dose interrupted in 43% and 57%, respectively [22] . A recent abstract by Billemont et al. reported that of 40 patients, 15 patients developed acute severe renal toxicity and the treatment dose was either decreased or interrupted in 12 patients. This phase II study defined acute severe renal toxicity as 'loss of 20 ml/min/1.73 m 2 CrCl, grade 3 proteinuria or hypertension' [23] . The present study also demonstrates that mRCC patients can develop renal insufficiency during treatment with sunitinib or sorafenib. Sunitinib more commonly required dose reduction in patients with RI at baseline (63% versus 38% for patients treated with sorafenib), and more cases of sunitinib-induced Cr elevation were identified. This is supported in other studies, particularly a systematic review and meta-analysis by Zhu et al., who looked at the risk associated with sunitinib. They found that sunitinib was associated with significant renal dysfunction and high-grade hypertension. They reported that the incidence of all-grade Cr increase was 65.6% among the patients with RCC receiving sunitinib when compared with controls [24] .
It is well recognized that following nephrectomy in a patient with previously normal kidneys, serum Cr increases as much as 20% [25] . Yoshinori et al. specifically studied the role of nephrectomy in RCC patients and found that glomerular filtration rate (GFR), which is a more accurate method of measuring renal function, increased on the average 40.5% at 1-year follow-up [26] . Though GFR is not routinely monitored while a patient undergoes treatment with VEGF therapy, monitoring of renal function via serum Cr is necessary during treatment with more frequent monitoring in patients with baseline renal insufficiency. An increase in serum Cr may require dose adjustment but not necessarily discontinuation of drug.
The metabolism of sunitinib and sorafenib provides further insight. Following oral administration, sorafenib and sunitinib are metabolized mostly by the liver, undergoing oxidative metabolism, mediated by CYP3A4 22. Nineteen percent and 16% of sorafenib and sunitinib, respectively, are excreted in the urine [24] . A recent phase I open-label parallel-group study which included eight patients on hemodialysis (HD) found that plasma exposure to sunitinib and its active metabolite were lower in HD patients than those patients with normal renal function [27] . Arterial and venous pharmacokinetic concentration data in this study indicated that this drug was not eliminated from the body via HD [27] . This study showed that a single dose of sunitinib was well tolerated in HD patients without serious toxic effects.
Our study is limited by the retrospective nature and the small number of patients. Furthermore, there was no uniform standard for dose adjustment, drug discontinuation or frequency/intensity of renal function monitoring.
conclusions Sunitinib and sorafenib can be safely given to patients with renal insufficiency, provided adequate monitoring of renal function. For those patients developing an increase in Cr, dose modifications may be required and may allow for continuation of therapy. The clinical outcome of patients with baseline renal dysfunction and patients who develop renal dysfunction does not appear to be compromised.
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